HELIUM, USP
Peakhelium, oxygen
NDAINHALATIONGAS
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HELIUM, USP is an inhalational gas product combining helium and oxygen, approved in 2013. It is administered via inhalation as a gaseous mixture. The mechanism of action is physical/respiratory support rather than pharmacological.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), indicating stable commercial operations and potential team consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HELIUM, USP offers exposure to specialty inhalational product management and hospital-based respiratory markets. Career growth is primarily in commercial execution, reimbursement strategy, and clinical education rather than product innovation.
Respiratory Specialty Sales RepresentativeHospital Account Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.